Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: Web-based multicenter registry study

Sukjoong Oh, Dong Hoe Koo, Min Jung Kwon, Kihyun Kim, Cheolwon Suh, Chang Ki Min, Sung Soo Yoon, Ho Jin Shin, Deog Yeon Jo, Jae Yong Kwak, Jinseok Kim, Sang Kyun Sohn, Young Don Joo, Hyeon Seok Eom, Sung Hyun Kim, Yang Soo Kim, Chulsoo Kim, Yeung Chul Mun, Hawk Kim, Dong Soon LeeJae Hoon Lee

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

This study was designed to evaluate the prevalence of chromosomal abnormalities and to identify the specific abnormalities associated with poor prognosis. A total of 2,474 patients whose conventional cytogenetics were available at the time of diagnosis were evaluated via a nationwide registry. Normal metaphase cytogenetics was observed in 2,012 patients (81.3%). Among the 462 patients with chromosomal abnormalities, there were 161 (34.8%) patients with hyperdiploidy, 197 (42.6%) with pseudodiploidy, 79 (17.1%) with hypodiploidy, and 25 (5.5%) with near-tetraploidy. Deletion 13 (Δ13) in metaphase was observed in 167 patients (6.8%). Fluorescent in situ hybridization (FISH) was carried out in 967 patients (39.1%), and 66 (13.7%) out of 482 and 63 (10.3%) out of 611 patients were positive for t(4;14) and del(17p), respectively. With a median follow-up duration of 25.1 months, the median overall survival (OS) was 51.2 months (95% confidence interval, 46.5-55.9 months). In univariate analysis, the following four chromosomal abnormalities were significantly associated with a poor survival outcome: Δ13, hypodiploidy, del(13q) in FISH, and del(17p) in FISH. In the subsequent multivariate analysis, in which del(13q) and del(17p) in FISH were excluded due to a relatively low number of patients, Δ13 and hypodiploid status were independently associated with a poor survival outcome after adjusting for important clinical factors, including age, sex, performance, beta2-microglobulin, albumin, and lactate dehydrogenase (LDH). Using conventional metaphase cytogenetics, we confirmed that both Δ13 and hypodiploid status were robust poor prognostic factors. The metaphase karyotyping should remain the primary cytogenetic tool and an essential investigation for risk stratification in newly diagnosed multiple myeloma patients.

Original languageEnglish
Pages (from-to)1353-1361
Number of pages9
JournalAnnals of Hematology
Volume93
Issue number8
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Chromosomes, Human, Pair 13
Chromosome Deletion
Multiple Myeloma
Cytogenetics
Multicenter Studies
Registries
Metaphase
Fluorescence In Situ Hybridization
Chromosome Aberrations
Survival
Karyotyping
Polyploidy
Tetraploidy
Age Factors
L-Lactate Dehydrogenase
Albumins
Multivariate Analysis
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Oh, Sukjoong ; Koo, Dong Hoe ; Kwon, Min Jung ; Kim, Kihyun ; Suh, Cheolwon ; Min, Chang Ki ; Yoon, Sung Soo ; Shin, Ho Jin ; Jo, Deog Yeon ; Kwak, Jae Yong ; Kim, Jinseok ; Sohn, Sang Kyun ; Joo, Young Don ; Eom, Hyeon Seok ; Kim, Sung Hyun ; Kim, Yang Soo ; Kim, Chulsoo ; Mun, Yeung Chul ; Kim, Hawk ; Lee, Dong Soon ; Lee, Jae Hoon. / Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients : Web-based multicenter registry study. In: Annals of Hematology. 2014 ; Vol. 93, No. 8. pp. 1353-1361.
@article{fa69ec9592eb49d7930d88912bde55a3,
title = "Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: Web-based multicenter registry study",
abstract = "This study was designed to evaluate the prevalence of chromosomal abnormalities and to identify the specific abnormalities associated with poor prognosis. A total of 2,474 patients whose conventional cytogenetics were available at the time of diagnosis were evaluated via a nationwide registry. Normal metaphase cytogenetics was observed in 2,012 patients (81.3{\%}). Among the 462 patients with chromosomal abnormalities, there were 161 (34.8{\%}) patients with hyperdiploidy, 197 (42.6{\%}) with pseudodiploidy, 79 (17.1{\%}) with hypodiploidy, and 25 (5.5{\%}) with near-tetraploidy. Deletion 13 (Δ13) in metaphase was observed in 167 patients (6.8{\%}). Fluorescent in situ hybridization (FISH) was carried out in 967 patients (39.1{\%}), and 66 (13.7{\%}) out of 482 and 63 (10.3{\%}) out of 611 patients were positive for t(4;14) and del(17p), respectively. With a median follow-up duration of 25.1 months, the median overall survival (OS) was 51.2 months (95{\%} confidence interval, 46.5-55.9 months). In univariate analysis, the following four chromosomal abnormalities were significantly associated with a poor survival outcome: Δ13, hypodiploidy, del(13q) in FISH, and del(17p) in FISH. In the subsequent multivariate analysis, in which del(13q) and del(17p) in FISH were excluded due to a relatively low number of patients, Δ13 and hypodiploid status were independently associated with a poor survival outcome after adjusting for important clinical factors, including age, sex, performance, beta2-microglobulin, albumin, and lactate dehydrogenase (LDH). Using conventional metaphase cytogenetics, we confirmed that both Δ13 and hypodiploid status were robust poor prognostic factors. The metaphase karyotyping should remain the primary cytogenetic tool and an essential investigation for risk stratification in newly diagnosed multiple myeloma patients.",
author = "Sukjoong Oh and Koo, {Dong Hoe} and Kwon, {Min Jung} and Kihyun Kim and Cheolwon Suh and Min, {Chang Ki} and Yoon, {Sung Soo} and Shin, {Ho Jin} and Jo, {Deog Yeon} and Kwak, {Jae Yong} and Jinseok Kim and Sohn, {Sang Kyun} and Joo, {Young Don} and Eom, {Hyeon Seok} and Kim, {Sung Hyun} and Kim, {Yang Soo} and Chulsoo Kim and Mun, {Yeung Chul} and Hawk Kim and Lee, {Dong Soon} and Lee, {Jae Hoon}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00277-014-2057-5",
language = "English",
volume = "93",
pages = "1353--1361",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "8",

}

Oh, S, Koo, DH, Kwon, MJ, Kim, K, Suh, C, Min, CK, Yoon, SS, Shin, HJ, Jo, DY, Kwak, JY, Kim, J, Sohn, SK, Joo, YD, Eom, HS, Kim, SH, Kim, YS, Kim, C, Mun, YC, Kim, H, Lee, DS & Lee, JH 2014, 'Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: Web-based multicenter registry study', Annals of Hematology, vol. 93, no. 8, pp. 1353-1361. https://doi.org/10.1007/s00277-014-2057-5

Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients : Web-based multicenter registry study. / Oh, Sukjoong; Koo, Dong Hoe; Kwon, Min Jung; Kim, Kihyun; Suh, Cheolwon; Min, Chang Ki; Yoon, Sung Soo; Shin, Ho Jin; Jo, Deog Yeon; Kwak, Jae Yong; Kim, Jinseok; Sohn, Sang Kyun; Joo, Young Don; Eom, Hyeon Seok; Kim, Sung Hyun; Kim, Yang Soo; Kim, Chulsoo; Mun, Yeung Chul; Kim, Hawk; Lee, Dong Soon; Lee, Jae Hoon.

In: Annals of Hematology, Vol. 93, No. 8, 01.01.2014, p. 1353-1361.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients

T2 - Web-based multicenter registry study

AU - Oh, Sukjoong

AU - Koo, Dong Hoe

AU - Kwon, Min Jung

AU - Kim, Kihyun

AU - Suh, Cheolwon

AU - Min, Chang Ki

AU - Yoon, Sung Soo

AU - Shin, Ho Jin

AU - Jo, Deog Yeon

AU - Kwak, Jae Yong

AU - Kim, Jinseok

AU - Sohn, Sang Kyun

AU - Joo, Young Don

AU - Eom, Hyeon Seok

AU - Kim, Sung Hyun

AU - Kim, Yang Soo

AU - Kim, Chulsoo

AU - Mun, Yeung Chul

AU - Kim, Hawk

AU - Lee, Dong Soon

AU - Lee, Jae Hoon

PY - 2014/1/1

Y1 - 2014/1/1

N2 - This study was designed to evaluate the prevalence of chromosomal abnormalities and to identify the specific abnormalities associated with poor prognosis. A total of 2,474 patients whose conventional cytogenetics were available at the time of diagnosis were evaluated via a nationwide registry. Normal metaphase cytogenetics was observed in 2,012 patients (81.3%). Among the 462 patients with chromosomal abnormalities, there were 161 (34.8%) patients with hyperdiploidy, 197 (42.6%) with pseudodiploidy, 79 (17.1%) with hypodiploidy, and 25 (5.5%) with near-tetraploidy. Deletion 13 (Δ13) in metaphase was observed in 167 patients (6.8%). Fluorescent in situ hybridization (FISH) was carried out in 967 patients (39.1%), and 66 (13.7%) out of 482 and 63 (10.3%) out of 611 patients were positive for t(4;14) and del(17p), respectively. With a median follow-up duration of 25.1 months, the median overall survival (OS) was 51.2 months (95% confidence interval, 46.5-55.9 months). In univariate analysis, the following four chromosomal abnormalities were significantly associated with a poor survival outcome: Δ13, hypodiploidy, del(13q) in FISH, and del(17p) in FISH. In the subsequent multivariate analysis, in which del(13q) and del(17p) in FISH were excluded due to a relatively low number of patients, Δ13 and hypodiploid status were independently associated with a poor survival outcome after adjusting for important clinical factors, including age, sex, performance, beta2-microglobulin, albumin, and lactate dehydrogenase (LDH). Using conventional metaphase cytogenetics, we confirmed that both Δ13 and hypodiploid status were robust poor prognostic factors. The metaphase karyotyping should remain the primary cytogenetic tool and an essential investigation for risk stratification in newly diagnosed multiple myeloma patients.

AB - This study was designed to evaluate the prevalence of chromosomal abnormalities and to identify the specific abnormalities associated with poor prognosis. A total of 2,474 patients whose conventional cytogenetics were available at the time of diagnosis were evaluated via a nationwide registry. Normal metaphase cytogenetics was observed in 2,012 patients (81.3%). Among the 462 patients with chromosomal abnormalities, there were 161 (34.8%) patients with hyperdiploidy, 197 (42.6%) with pseudodiploidy, 79 (17.1%) with hypodiploidy, and 25 (5.5%) with near-tetraploidy. Deletion 13 (Δ13) in metaphase was observed in 167 patients (6.8%). Fluorescent in situ hybridization (FISH) was carried out in 967 patients (39.1%), and 66 (13.7%) out of 482 and 63 (10.3%) out of 611 patients were positive for t(4;14) and del(17p), respectively. With a median follow-up duration of 25.1 months, the median overall survival (OS) was 51.2 months (95% confidence interval, 46.5-55.9 months). In univariate analysis, the following four chromosomal abnormalities were significantly associated with a poor survival outcome: Δ13, hypodiploidy, del(13q) in FISH, and del(17p) in FISH. In the subsequent multivariate analysis, in which del(13q) and del(17p) in FISH were excluded due to a relatively low number of patients, Δ13 and hypodiploid status were independently associated with a poor survival outcome after adjusting for important clinical factors, including age, sex, performance, beta2-microglobulin, albumin, and lactate dehydrogenase (LDH). Using conventional metaphase cytogenetics, we confirmed that both Δ13 and hypodiploid status were robust poor prognostic factors. The metaphase karyotyping should remain the primary cytogenetic tool and an essential investigation for risk stratification in newly diagnosed multiple myeloma patients.

UR - http://www.scopus.com/inward/record.url?scp=84904717814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904717814&partnerID=8YFLogxK

U2 - 10.1007/s00277-014-2057-5

DO - 10.1007/s00277-014-2057-5

M3 - Article

C2 - 24671365

AN - SCOPUS:84904717814

VL - 93

SP - 1353

EP - 1361

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 8

ER -